The Patent Finder

Palatin Technologies, Inc.

Also on record
Records under this name other than the patents Palatin Technologies, Inc. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned. None of them is counted in the 31 patents it holds.

Back to Palatin Technologies, Inc.

PatentTitleStatus Expires Confidence
US 7,727,990Melanocortin Receptor-Specific Piperazine and Keto-Piperazine Compounds
Term ended
Term ended May 21, 2026 · High confidence
Term endedTerm ended May 21, 2026High confidence
US 7,727,991Substituted Melanocortin Receptor-Specific Single Acyl Piperazine Compounds
Term ended
Term ended Jan 1, 2026 · High confidence
Term endedTerm ended Jan 1, 2026High confidence
US 8,580,746Amide linkage cyclic natriuretic peptide constructs
Lapsed on the fee record
Ended Nov 12, 2025 · From the USPTO record
Lapsed on the fee recordEnded Nov 12, 2025From the USPTO record
US 8,580,747Cyclic natriuretic peptide constructs
Lapsed on the fee record
Ended Nov 12, 2025 · From the USPTO record
Lapsed on the fee recordEnded Nov 12, 2025From the USPTO record
US 6,794,489Compositions and methods for treatment of sexual dysfunction
Formerly held
Term ended
Term ended Nov 11, 2025 · From the USPTO record
Term endedTerm ended Nov 11, 2025From the USPTO record
US 7,732,451Naphthalene-Containing Melanocortin Receptor-Specific Small Molecule
Term ended
Term ended Aug 10, 2025 · Medium confidence
Term endedTerm ended Aug 10, 2025Medium confidence
US 7,235,625Multiple agent therapy for sexual dysfunction
Term ended
Term ended May 26, 2025 · From the USPTO record
Term endedTerm ended May 26, 2025From the USPTO record
US 7,718,802Substituted Melanocortin Receptor-Specific Piperazine Compounds
Term ended
Term ended Apr 16, 2025 · Medium confidence
Term endedTerm ended Apr 16, 2025Medium confidence
US 7,417,027Linear and cyclic melanocortin receptor-specific peptides
Term ended
Term ended Feb 1, 2024 · From the USPTO record
Term endedTerm ended Feb 1, 2024From the USPTO record
US 7,968,548Melanocortin Receptor-Specific Piperazine Compounds with Diamine Groups
Lapsed on the fee record
Ended Jun 28, 2023 · High confidence
Lapsed on the fee recordEnded Jun 28, 2023High confidence
10 of 40 patents shown.
Pro members see all 40.
Pro members: see all 40 patents
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 16, 2026 · includes USPTO assignment & status data published Nov 16, 2026 and grant & fee data published Nov 10, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited